These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 10070945)

  • 1. Statistical analysis of array expression data as applied to the problem of tamoxifen resistance.
    Hilsenbeck SG; Friedrichs WE; Schiff R; O'Connell P; Hansen RK; Osborne CK; Fuqua SA
    J Natl Cancer Inst; 1999 Mar; 91(5):453-9. PubMed ID: 10070945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.
    Osborne CK; Coronado-Heinsohn EB; Hilsenbeck SG; McCue BL; Wakeling AE; McClelland RA; Manning DL; Nicholson RI
    J Natl Cancer Inst; 1995 May; 87(10):746-50. PubMed ID: 7563152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro.
    Kurebayashi J; Otsuki T; Yamamoto S; Kurosumi M; Nakata T; Akinaga S; Sonoo H
    Oncology; 1998 Dec; 55 Suppl 1():23-34. PubMed ID: 9852399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
    Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta.
    Arteaga CL; Koli KM; Dugger TC; Clarke R
    J Natl Cancer Inst; 1999 Jan; 91(1):46-53. PubMed ID: 9890169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo.
    Schiff R; Reddy P; Ahotupa M; Coronado-Heinsohn E; Grim M; Hilsenbeck SG; Lawrence R; Deneke S; Herrera R; Chamness GC; Fuqua SA; Brown PH; Osborne CK
    J Natl Cancer Inst; 2000 Dec; 92(23):1926-34. PubMed ID: 11106684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1.
    Ming J; Ruan S; Wang M; Ye D; Fan N; Meng Q; Tian B; Huang T
    Oncotarget; 2015 Dec; 6(38):40692-703. PubMed ID: 26517687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
    Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response.
    van Agthoven T; Sieuwerts AM; Meijer D; Meijer-van Gelder ME; van Agthoven TL; Sarwari R; Sleijfer S; Foekens JA; Dorssers LC
    Endocr Relat Cancer; 2010 Mar; 17(1):215-30. PubMed ID: 19966015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-33 facilitates endocrine resistance of breast cancer by inducing cancer stem cell properties.
    Hu H; Sun J; Wang C; Bu X; Liu X; Mao Y; Wang H
    Biochem Biophys Res Commun; 2017 Apr; 485(3):643-650. PubMed ID: 28216163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer.
    Taylor KJ; Sims AH; Liang L; Faratian D; Muir M; Walker G; Kuske B; Dixon JM; Cameron DA; Harrison DJ; Langdon SP
    Breast Cancer Res; 2010; 12(3):R39. PubMed ID: 20569502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
    Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
    J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
    Lykkesfeldt AE; Madsen MW; Briand P
    Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells.
    van Agthoven T; van Agthoven TL; Dekker A; van der Spek PJ; Vreede L; Dorssers LC
    EMBO J; 1998 May; 17(10):2799-808. PubMed ID: 9582273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new class of small molecule estrogen receptor-alpha antagonists that overcome anti-estrogen resistance.
    Ma Y; Preet A; Tomita Y; De Oliveira E; Zhang L; Ueda Y; Clarke R; Brown M; Rosen EM
    Oncotarget; 2015 Dec; 6(38):40388-404. PubMed ID: 26575173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells.
    Frankel LB; Lykkesfeldt AE; Hansen JB; Stenvang J
    Breast Cancer Res Treat; 2007 Aug; 104(2):165-79. PubMed ID: 17061041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells.
    Brinkman A; van der Flier S; Kok EM; Dorssers LC
    J Natl Cancer Inst; 2000 Jan; 92(2):112-20. PubMed ID: 10639512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ.
    Lü M; Ding K; Zhang G; Yin M; Yao G; Tian H; Lian J; Liu L; Liang M; Zhu T; Sun F
    Sci Rep; 2015 Mar; 5():8735. PubMed ID: 25736597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
    Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC
    Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.